Three second‐generation anti‐CD19 CAR T‐cell therapies have demonstrated efficacy and safety in Japan for patients with R/R aggressive B‐cell NHL: tisagenlecleucel,10 axicabtagene ciloleucel,9 and, with this report, liso‐cel. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.